Most Clicked StoriesMore >


Boehringer Ingelheim to partner with Peking University on drug research

BIO SmartBrief | May 17, 2017

Boehringer Ingelheim has agreed to work with Peking University to identify targets and develop medicines for cancer, cancer immunology and immune modulation, respiratory conditions and cardiometabolic and central nervous system diseases, as well as gene therapies and regenerative drugs. BioCentury (05/16)


Akebia signs $50M distribution deal with Vifor

BIO SmartBrief | May 16, 2017

Merck expands clinical collaboration with Aduro

BIO SmartBrief | May 18, 2017

Corbin signs deal with Proteorex for neuroinflammatory disease drug R&D

BIO SmartBrief | May 22, 2017

Merck's Keytruda approved for 2 bladder cancer indications

BIO SmartBrief | May 19, 2017

Cancer drug developer gets $125M funding boost

BIO SmartBrief | May 22, 2017

Drug for Alzheimer's indication to be developed in Cuba

BIO SmartBrief | May 16, 2017

Imara's sickle cell disease candidate gets rare pediatric disease designation

BIO SmartBrief | May 17, 2017

Pediatric leukemia drug from Abon Pharma gains FDA approval

BIO SmartBrief | May 22, 2017

Keytruda gets FDA accelerated approval for Hodgkin lymphoma treatment

BIO SmartBrief | May 18, 2017


Find BIO SmartBrief Issues by Date:



BIO News More >


BIO business solutions -- Latest

BIO SmartBrief | May 22, 2017

Registration for BIO 2017 World Congress now open

BIO SmartBrief | May 22, 2017

Airgas

BIO SmartBrief | May 19, 2017

Register for BIO Talent Connect, BIO's Career Growth Opportunity at BIO 2017

BIO SmartBrief | May 18, 2017

Is your perishable property protected?

BIO SmartBrief | May 18, 2017




Sign up for BIO SmartBrief



Designed specifically for biotechnology industry professionals like you, BIO SmartBrief is a FREE daily e-mail newsletter. It provides the latest news and information you need to stay informed about important biotech issues. Learn more